A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants  by Bustamante, Leyla Y. et al.
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The  lack  of an effective  licensed  vaccine  remains  one  of the  most  signiﬁcant  gaps  in the  portfolio  of  tools
being  developed  to eliminate  Plasmodium  falciparum  malaria.  Vaccines  targeting  erythrocyte  invasion  –
an essential  step  for both  parasite  development  and malaria  pathogenesis  –  have  faced  the particular
challenge  of  genetic  diversity.  Immunity-driven  balancing  selection  pressure  on  parasite  invasion  pro-
teins  often  results  in the  presence  of  multiple,  antigenically  distinct,  variants  within  a population,  leading
to variant-speciﬁc  immune  responses.  Such  variation  makes  it difﬁcult  to design  a  vaccine  that  covers  the
full range  of diversity,  and  could  potentially  facilitate  the  evolution  of  vaccine-resistant  parasite  strains.
In this  study,  we investigate  the effect  of  genetic  diversity  on  invasion  inhibition  by antibodies  to  a  high
priority  P. falciparum  invasion  candidate  antigen,  P.  falciparum  Reticulocyte  Binding  Protein  Homologue  5
(PfRH5).  Previous  work  has  shown  that  virally  delivered  PfRH5  can induce  antibodies  that  protect  against
a wide  range  of  genetic  variants.  Here,  we show  that  a full-length  recombinant  PfRH5  protein  expressed
in mammalian  cells  is biochemically  active,  as  judged  by  saturable  binding  to  its  receptor,  basigin,  and  is
able to  induce  antibodies  that  strongly  inhibit  P.  falciparum  growth  and  invasion.  Whole  genome  sequenc-
ing  of  290  clinical  P. falciparum  isolates  from  across  the  world  identiﬁes  only  ﬁve non-synonymous  PfRH5
SNPs  that  are  present  at frequencies  of  10%  or more  in  at least  one  geographical  region.  Antibodies  raised
against  the  3D7  variant  of PfRH5  were  able  to  inhibit  nine  different  P. falciparum  strains,  which  between
them  included  all of  the  ﬁve  most  common  PfRH5  SNPs  in  this  dataset,  with  no  evidence  for  strain-
speciﬁc  immunity.  We  conclude  that  protein-based  PfRH5  vaccines  are  an urgent  priority  for  human
efﬁcacy  trials.. Introduction
The development of an effective Plasmodium falciparum vac-
ine is the topic of intense research. Rational arguments can
e advanced to support vaccines that target pre-erythrocytic or
rythrocytic stages in humans, or parasite development within
he mosquito [1]. The number of stages that could be targeted is
ompounded by the variety of potential approaches [2],  which
ange from genetically or physically attenuated parasites [3],  to
ubunit-based vaccines, of which there are hundreds of theoretical
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targets within the genome [4].  Regardless of the approach, how-
ever, the fundamental requirement for an effective malaria vaccine
is the same – to effectively protect the largest number of people
against the widest possible range of P. falciparum genetic variants.
Vaccines targeting the erythrocytic stage have their origins
in the observations that passive transfer of immunoglobulins
from immune to non-immune individuals markedly reduced para-
sitemia [5],  and that immune adults directly inoculated with blood
stage parasites avoid clinical symptoms, emphasizing the protec-
tive effect of antibodies targeting blood-stage antigens [6].  Several
P. falciparum proteins have been suggested as potential blood-
stage vaccine antigens, either because of their function, localization
on the merozoite surface, or because data from immuno epi-
demiological studies suggest that they are targets of protective
Open access under CC BY license.immunity [7,8]. All face the same fundamental challenge, however;
by being directly exposed to the human immune system during
natural infections, they are under considerable selective pressure,
which can result in high levels of polymorphism [9],  meaning that
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accine-induced immunity must be able to protect against multiple
enetic variants. Although this is a signiﬁcant challenge, the avail-
bility of genome sequences for hundreds of P. falciparum isolates
10] now makes it possible to measure the true scale of the chal-
enge by identifying for each antigen which residues are variable,
nd in which populations.
P. falciparum Reticulocyte Binding Protein Homologue 5 (PfRH5)
s a member of the super family of erythrocyte ligands referred to as
he Reticulocyte Binding Like proteins (RBLs), at least one member
f which is found in every Plasmodium genome [11]. PfRH5 differs
rom the other members of the PfRH family in that it is much smaller
nd the gene encoding PfRH5is refractory to genetic deletion in all
ested strains, implying that it is essential for blood-stage growth
12]. PfRH5 bindserythrocytes and is implicated in the species
ropism of erythrocyte invasion [12–14],  and our laboratories
ave recently established that the receptor for PfRH5 is basi-
in/CD147 [15]. Of key importance for vaccine development is that
nlike all other known erythrocyte–merozoite receptor–ligand
nteractions, the basigin-PfRH5 interaction was essential for eryth-
ocyte invasion in every P. falciparum strain tested to date
15].
Its role in a universally required merozoite–erythrocyte inter-
ction clearly highlightsPfRH5 as a promising vaccine target.
owever, early studies using antibodies raised against sub frag-
ents of recombinant PfRH5 expressed in E. coli showed no [14] or
ery limited [12] efﬁcacy in blood stage growth inhibition assays
GIAs). By contrast, immunization with recombinant viruses encod-
ng full-length PfRH5 produced antibodies that cross-protected
gainst multiple P. falciparum strains [16] suggesting that the con-
ormation of the PfRH5 protein used as an antigen was critical
or this activity. Here, we set out to establish whether full-length,
unctional, PfRH5 protein could induce growth-inhibiting antibod-
es. At the same time, we performed a systematic investigation
f the impact of genetic diversity on invasion inhibitory activ-
ty, by testing anti-PfRH5 antibodies against P. falciparum strains
hat contained all common genetic variants of PfRH5,  as deﬁned
n sequencing study of 227 P. falciparum clinical isolates [10].
he data has important implications for the vaccine candidacy of
fRH5.
. Materials and methods
.1. Parasite sequence variant analysis
Single nucleotide polymorphisms (SNPs) and allele frequen-
ies were obtained from a published analysis of 227 clinical P.
alciparum infections [10]. MalariaGen SNP catalogue release
.0 data was used for all analysis (www.malariagen.net/data).
fRH5 sequence was veriﬁed for all strains used (see
upplement).
.2. Protein expression plasmids, production and puriﬁcation
Expression of the P. falciparum 3D7 PfRH5 ectodomain was
escribed previously [15], and 7G8 and GB4 PfRH5 variants and
D7 AMA1 were made and expressed according to the same
rinciples. The basigin-L ectodomain was expressed as a soluble
d4d3+4-hexa-his tagged protein, as described [17]. All proteins
ere produced as secreted proteins by the human HEK293E cell
ine grown in suspension and transiently transfected at a density of
x105 cells per mL  as described [17,18]. His-tagged proteins were
uriﬁed from spent supernatants after transient transfections on
isTrapTM HP columns (GE Healthcare) using an ÄKTAxpressTM (GE
ealthcare).ne 31 (2013) 373– 379
2.3. Surface plasmon resonance
Surface plasmon resonance (SPR) studies were performed using
a BIAcoreTM T100 (GE Healthcare). Monomeric biotinylated bait
proteins were immobilized on a streptavidin-coated sensor chip
(GE Healthcare) and increasing concentrations of puriﬁed basigin
was injected at 20 l/min to determine equilibrium measurements
or 100 l/min for kinetic parameters. Both equilibrium and kinetic
binding data were analyzed in the manufacturer’s BIAcoreTM T100
evaluation software (GE Healthcare).
2.4. Enzyme-linked immunosorbant assay (ELISAs)
Monobiotinylated proteins were captured on streptavidin-
coated plates (Nunc) and then incubated for 90 min with 1 g/ml
primary antibody from which anti-Cd4 reactivity had been
removed by preadsorbing with Cd4 protein. Alkaline phosphatase-
linked secondary antibodies and appropriate detection reagents
(Sigma) were used, and optical density measurements taken at
405 nm (Pherastar plus, BMG  laboratories).
2.5. Antibodies
Polyclonal antisera against 3D7 PfRH5 and AMA1 were raised
commercially and in parallel (Cambridge Research Biochemicals,
Billingham, UK; immunization regime listed in Supplement). The
use of animals to raise antisera was  performed according to UK
Home Ofﬁce governmental regulations and approved by the local
Sanger Institute ethical review board. Total IgG from the sera
were puriﬁed on Hi-TrapTM Protein G HP columns (GE Healthcare)
according to the manufacturer’s instructions.
2.6. P. falciparum culture and invasion assays
P. falciparum parasites were cultured in human O+ erythrocytes
at 5% hematocrit. Field strains were conﬁrmed to contain only a
single strain using PfMSP1 and PfMSP2 genotyping. Use of erythro-
cytes and serum from human donors was approved by the NHS
Cambridgeshire 4 Research Ethics Committee, and all donors sup-
plied written informed consent. For invasion assays, synchronized
parasites were incubated in the presence or absence of antibod-
ies for 24 h. Invasion assays were carried out in 96 well plates,
with 3 identical wells set up for each strain/antibody concentration
combination. Cultures were then ﬁxed, and parasitized erythro-
cytes counted using SYBR Green I (Invitrogen) and ﬂow cytometry,
as described previously [19]. Invasion efﬁciency was calculated by
comparing invasion in the presence of a given antibody concentra-
tion to invasion in the absence of antibodies.
3. Results
3.1. Genetic diversity in PfRH5 is limited
Whole genome sequencing by the MalariaGen consortium of
227 P. falciparum clinical isolates (125 samples from Africa (Mali,
Burkina Faso and Kenya), 81 samples from Southeast Asia (Thailand
and Cambodia) and 21 samples from Papua New Guinea [10]) iden-
tiﬁed fourteen polymorphisms in the PfRH5 gene, two of which are
synonymous and twelve non-synonymous (Table 1). This excess of
non-synonymous over synonymous mutations is consistent with
the overall trend of mutation rates in the P. falciparum genome
and the speciﬁc increase in non-synonymous substitutions in
proteins exposed on the merozoite surface [20]. Of the twelve non-
synonymous mutations, only ﬁve SNPs reach a frequency greater
than 10% in at least one population (Y147H, H148D, S197Y, C203Y
and I410 M;  marked * in Table 1), and can be considered the most
L.Y. Bustamante et al. / Vacci
Table 1
Global allele frequencies of PfRH5 sequence variants in clinical isolates.
AA 3D7 Nref Freq Africa Freq Asia Freq PNG Lab strain
88 N D 0.01 0.00 0.00 –
147* Y H 0.09 0.28 0.05 –
148* H D 0.10 0.30 0.05 –
197* S Y 0.00 0.54 0.38 FCR1
203* C Y 0.79 0.62 0.9 FCR1, GB4
233 A E 0.00 0.00 0.05 –
365 H N 0.01 0.00 0.00 –
371 V I 0.05 0.00 0.00 –
407 I V 0.03 0.00 0.00 GB4
410* I M 0.00 0.35 0.10 Dd2
477 Q H 0.01 0.00 0.00 –
493 I V 0.00 0.00 0.00 –
Publically available aggregate data from the sequencing of 227 P. falciparum clinical
isolates by the MalariaGen consortium [10] was searched for single nucleotide poly-
morphisms (SNPs) in PfRH5.  Only SNPs that cause a change in amino acid (AA) at a
speciﬁc position relative to the reference P. falciparum sequence (3D7), are included
and are referred to as non-reference SNPs (Nref) in the v1.0 SNP catalogue. The allele
frequency for each non-ref PfRH5 SNP in the 125 African, 81 Asian and 21 Papua New
Guinean (PNG) samples are listed above. SNPs present in at least 10% of at least one
population are judged to be common, and are indicated by an asterisk ‘*’. SNPs iden-
tiﬁed in previously published PfRH5 sequences for laboratory-adapted P. falciparum
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rsolates [13] are listed. Note that most naturally varying SNPs have not yet been
dentiﬁed in laboratory strains.
ommon global variants in PfRH5 that have been currently identi-
ed. Of these ﬁve SNPs, three are found in previously sequenced
aboratory-adapted P. falciparum strains, but Y147H and H148D,
hich reach 30% frequency in Southeast Asian clinical isolates, are
ot present in any lab strain sequenced to date (Table 1). We  identi-
ed two isolates from Cambodia that contained these mutations for
se in this study. PfRH5 sequences from all strains was conﬁrmed
y sequencing, and the full haplotype of each strain is shown in
upplementary Table 1.
.2. Expression and puriﬁcation of biochemically active
ull-length recombinant PfRH5 protein variants
The chances of raising an effective polyclonal antibody response
re likely to be signiﬁcantly higher if the recombinant antigen
losely mimics the conformation of the native antigen [21]. Pre-
iously, we have shown that biochemically active PfRH5 can be
xpressed as a secreted full-length protein using a mammalian
xpression system [15]. The 3D7 variant of PfRH5 was  used in
hese initial experiments, which is notable because it contains
ix cysteine residues of which C203 is a relatively rare variant,
eaning most strains express PfRH5 with ﬁve cysteines (Table 1).
s sulfhydryl groups of cysteines are normally oxidized to form
tructurally critical disulﬁde bonds in secreted proteins, polymor-
hism at C203 suggests that cysteine residues in some variants of
fRH5, most likely at positions 203 and 329, are unpaired [12].
o determine whether PfRH5 variants that contain ﬁve cysteines
ere biochemically active, we expressed 7G8 and GB4 variantsin
EK239E cells as Cd4d3+4-tagged monobiotinylated “bait” pro-
eins [17]. Cells were transiently transfected, and all variants
roduced 2–10 g of protein per ml  of cell culture supernatant
 days post-transfection. These yields were produced using a
ost-effective transfection approach, which typically resulted in a
ransfection efﬁciency of ∼40%, and could presumably be increased
n stably expressing isolates.
To test variants for biochemical activity, we  expressed and
uriﬁed the extracellular region of human basigin as a soluble
d4d3+4-6H-tagged protein and used surface plasmon resonance
o quantify interaction afﬁnities. Serial dilutions of basigin were
njected over PfRH5 immobilized on a sensor chip until equilib-
ium was reached (Fig. 1A). Saturable binding was  observed, andne 31 (2013) 373– 379 375
the biophysical binding parameters were very similar in all cases
(Supplementary Table 2). The association (ka) and dissociation (kd)
kinetic rate constants were in good agreement with the equilibrium
analysis (Supplementary Table 2), providing an independent mea-
sure of the interaction parameters. The KD was essentially identical
to that reported for the same experiment performed in the recip-
rocal orientation using puriﬁed 3D7 PfRH5 [15] suggesting that the
proportion of biochemically active protein was  high.
3.3. Generation of polyclonal antisera and testing against PfRH5
variants
To raise polyclonal antisera against full-length 3D7 PfRH5, we
expressed and puriﬁed the protein as previously described [15].
Puriﬁed PfRH5-Cd4d3+4-6H runs as two  bands at ∼85 and ∼65 kDa
(Fig. 1B), which, when the size of the Cd4 tag (∼25 kDa) is taken
into account, corresponds well to the two forms of native PfRH5 (63
and 45 kDa) observed in parasite cultures [12], suggesting the same
proteolytic processing occurs when expressed in HEK293 cells as
in the parasite. We  were able to resolve the 85 kDa band from the
65 kDa form by size-exclusion chromatography (Fig. 1B). Puriﬁed
PfRH5 protein showed no measurable loss of activity when stored
at 4 ◦C for several months (unpublished observations). Rabbits were
immunized with 1 mg  of puriﬁed 3D7 PfRH5-Cd4d3+4-6H pro-
tein. To remove anti-Cd4 antibodies, the antisera were preadsorbed
with a Cd4-tag-containing protein and shown to then lack anti-
Cd4 immunoreactivity by ELISA (Fig. 2A). Preadsorbed total IgG
was then used in ELISAs to quantify the immuno reactivity against
both the immunizing 3D7 antigen, and cross-reaction with the 7G8
and GB4 variants. No difference in immuno reactivity to any of the
three variants was  observed (Fig. 2A). We  heat-treated 3D7 PfRH5
and observed a loss of immuno reactivity suggesting that a good
proportion of the antibodies recognized heat-labile conformational
epitopes (Fig. 2B).
3.4. Antibodies raised against the 3D7 PfRH5 variant inhibit
parasites that collectively include all currently identiﬁed common
PfRH5 genetic variants
To establish whether antibodies raised against the full-length
3D7 variant of PfRH5 could inhibit erythrocyte invasion, total IgG
was puriﬁed from anti-PfRH5 rabbit polyclonal serum and added
in increasing concentrations to late trophozoite stage P. falcipa-
rum parasite cultures. Parasites were cultured in the presence of
IgG for 24 hours before parasitemia was  measured using a ﬂuo-
rescent DNA dye [19]. Anti-PfRH5 IgG had a clear dose-dependent
inhibitory effect on the growth of 3D7 parasites, with an IC50 of
1.9 mg/ml  total IgG (Fig. 3A). FCR1 was chosen for initial strain-
speciﬁcity trials because it contains two of the ﬁve common PfRH5
SNPs (Table 1). Dose–response curves for inhibition of FCR1 para-
sites were similar to those against 3D7, with an IC50 of 3.1 mg/ml
total IgG. (Fig. 3A). By contrast, antibodies raised against the entire
ectodomain of the 3D7 variant of AMA1 had a marked strain-
speciﬁc effect, with only a 40% reduction in FCR1 growth even at
the maximum concentration of 10 mg/ml  (Fig. 3B), consistent with
the known strain-speciﬁc properties of anti-AMA1 antibodies [22].
Neither strain was  inhibited by control pre-immune rabbit total IgG
(Fig. 3C).
To more comprehensively test the inhibitory effect of antibodies
raised against the 3D7 variant of PfRH5, we tested seven additional
P. falciparum isolates, that between them included PfRH5 sequences
that encompass the ﬁve common PfRH5 SNPs. The effect of anti-
PfRH5 on 3D7 was  re-measured in every replicate as a positive
control. The dose-response curves for laboratory (Fig. 4A), Kenyan
(Fig. 4B) and Cambodian strains (Fig. 4C) were broadly comparable
with that of 3D7. As expected, the inhibitory effect varied slightly
376 L.Y. Bustamante et al. / Vaccine 31 (2013) 373– 379
Fig. 1. Surface plasmon resonance demonstrates biochemical activity of recombinant full-length 7G8 PfRH5-Cd4. (A) 7G8 PfRH5-Cd4-biotin was speciﬁcally captured in a
ﬂow  cell of a streptavidin-coated chip using an approximate molar equivalent of Cd4-biotin immobilized in a neighbouring ﬂow cell used as a reference. Serial dilutions of
puriﬁed  basigin-Cd4-6H were injected until equilibrium was reached (solid bar, inset) and reference-subtracted data were used to plot the binding responses once equilibrium
had  been achieved. An equilibrium dissociation constant was calculated using non-linear regression ﬁtting of a simple Langmuir binding isotherm to the data (solid line).
Note  that the binding was  saturable and therefore speciﬁc and a KD of 0.9 ± 0.13 M (mean ± SEM) was calculated from two  independent experiments (see Supplementary
Table  2). A representative experiment using 7G8 is shown, equilibrium constants for 3D7 and GB4 were calculated in the same way and are reported in Supplementary Table
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educing conditions. The 85 kDa protein, which is consistent with the expected si
5kDa  band using size exclusion chromatography (post-SEC).
etween independent experiments due to biological variation, such
s different starting growth rates. To enable a quantitative com-
arison between experiments, the IC50 for each test strain was
ompared to that of the 3D7 positive control reference strain per-
ormed in parallel. IC50 ratios are listed in the ﬁgure legends, and
ange from a low of 0.53 (Kenya KCC103) to a high of 1.6 (FCR1).
tatistical analysis (f-test) established that no IC50 represents a
igniﬁcant variation from 3D7 (p = 0.623). Serum from a second
abbit immunized with full-length 3D7 PfRH5 were also tested and
howed no signiﬁcant difference in growth inhibition between 3D7
nd FCR1 parasites (data not shown). Antibodies raised against the
D7 PfRH5 variant therefore have broad inhibitory activity across
ll currently identiﬁed common genetic variants, with no evidence
or signiﬁcant variant-speciﬁcity.
. DiscussionThe essentiality of the PfRH5–basigin interaction for erythrocyte
nvasion across all strains tested [15] have highlighted PfRH5 as a
articularly promising blood-stage vaccine candidate. The devel-
pment of subunit malaria vaccines has, however, been partly
ig. 2. Immunoreactivities to recombinant PfRH5 7G8 and GB4 are indistinguishable from t
ines,  as indicated in the key) were expressed as Cd4-biotin tagged recombinant protein
ach  variant was  equally immunoreactive to a polyclonal antiserum that was  raised using
he  antiserum against Cd4; the preadsorbed antiserum was shown to lack anti-Cd4 immu
D7  variant of PfRH5-Cd4-biotin was again captured on a streptavidin-coated plate eithe
ere  tested for their immunoreactivity to the anti-RH5 polyclonal antiserum that had bee
epresent SEM; n = 3.wo bands (∼85 and 65 kDa) using using Coomassie staining after SDS-PAGE under
the full-length PfRH5-Cd4-d3+4-6 H protein, could be separated from the smaller
limited by the technical difﬁculties of expressing biochemically
active Plasmodium proteins in heterologous expression systems
[23]. While viral delivery systems could be considered [24], blood-
stage vaccines based on proteins could be more easily combined
with vaccines targeting other stages of the Plasmodium lifecycle
such as RTS, S [25]. Using a mammalian expression system, we  have
been able to produce full-length PfRH5 protein and unambiguously
demonstrate its biochemical activity by showing saturable binding
to its receptor, basigin [15]. While other assays such as erythro-
cyte binding and immuno reactivity to parasite-exposed sera have
traditionally been used to validate the function of recombinant par-
asite proteins, these assays might not be sufﬁcient to assess correct
folding and biochemical activity, which are well-recognized pre-
requisites of good vaccine antigens. The identiﬁcation of basigin
as the erythrocyte PfRH5 receptor now enables the unequivocal
testing of the biochemical activity of any recombinantly produced
PfRH5 in a quantiﬁable manner. It remains to be seen whether
recombinant RH5 protein produced either using E. coli with a
refolding protocol [12], a wheat germ lysate system [26], or used
chemically synthesized peptides [27], has this conﬁrmed biochem-
ical activity.
he 3D7 variant used as an antigen. (A) The 3D7, 7G8 and GB4 PfRH5 variants (colored
s, normalized, and speciﬁcally captured on a streptavidin-coated microtitre plate.
 the 3D7 variant. Immunoreactivity to the Cd4 tag was  removed by preadsorption of
noreactivity (black line). (B) Recombinant PfRH5 contains heat-labile epitopes. The
r without treatment or after denaturation by heat (80 ◦C, 10 min). The two  proteins
n preadsorbed against Cd4 (shown as a control). Data points are means; error bars
L.Y. Bustamante et al. / Vaccine 31 (2013) 373– 379 377
Fig. 3. Polyclonal antibodies raised against 3D7 PfRH5 inhibit both 3D7 and FCR1 P.
falciparum parasites. (A) Total IgG puriﬁed from a rabbit immunized with the 3D7
variant of PfRH5 was  used in invasion assays with the 3D7 and FCR1 P. Falciparum
strains. Growth inhibition was observed to a similar extent for both strains with an
IC50 ratio for FCR1 of 1.6 (95% CI 1.17–2.18). (B) Total IgG puriﬁed from a rabbit
immunized with the 3D7 AMA  variant was used in erythrocyte invasion assays with
the 3D7 or FCR1 P. Falciparum strains and showed strain-speciﬁc growth inhibition.
(C) Total IgG puriﬁed from unimmunized rabbits was used in erythrocyte invasion
assays with the 3D7 or FCR1 P. falciparum strains and had no inhibitory effect on
erythrocyte invasion. Each IgG concentration/strain combination was  assayed in
three wells in a 96 well plate; data points are means of all three wells, with standard
deviation error bars shown.
Fig. 4. Polyclonal antibodies raised against 3D7 PfRH5 inhibit P. falciparum strains
that  collectively include all common PfRH5 variants. (A) Total IgG puriﬁed from a
rabbit immunized with the 3D7 variant of PfRH5 was used in invasion assays with
Dd2, 7G8, GB4 and 3D7P. falciparum strains. IC50 ratios were 0.5, 1.0 and 1.4 for
Dd2, 7G8 and GB4, respectively. 95% CI for IC50s were 0.47–0.63 (Dd2), 0.71–1.36
(7G8) and 1.18–1.71 (GB4). (B) Total IgG puriﬁed from a rabbit immunized with the
3D7  variant of PfRH5 was  used in erythrocyte invasion assays with two P. falciparum
isolates from Kenya (K7336 and KCC103), and the 3D7 P. falciparum strain. IC50 ratios
were 1.1 and 0.5 for K7336 and KCC103, respectively. 95% CI for IC50s were 0.81–1.42
(K7336) and 0.35–0.76 (KCC103). (C) Total IgG puriﬁed from a rabbit immunized
with the 3D7 variant of PfRH5 was used in erythrocyte invasion assays with two  P.
falciparum isolates from Cambodia (PH21 and PH22) and the 3D7 P. falciparum strain.
IC50  ratios were 0.8 and 1.3 for PH21 and PH22 respectively. 95% CI for IC50s were
0.59–1.35 (PH21) and 0.93–1.76 (PH22). Each IgG concentration/strain combination
was  assayed in three wells in a 96 well plate; data points are means of all three wells,
with standard deviation error bars shown.
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Using a recombinant PfRH5 based on the 3D7 sequence of P.
alciparum, we were able to raise antibodies that have growth
nhibitory effects across multiple P. falciparum strains. Genetic
iversity in blood-stage vaccine candidates is a concern because
f the risk of raising allele-speciﬁc antibody responses, and such
esponses have been observed for multiple P. falciparum mero-
oite proteins, including those advanced for human trials such
s MSP1 [28], MSP3 [28–30] and AMA1 [22]. Interrogation of the
hole genome sequences of 227 clinical P. falciparum isolates [10]
howed that the gene encoding PfRH5 has only a few SNPs present
t high frequency. This might be due to the fact that PfRH5 is
ot a target of natural humoral immunity since, remarkably, sera
rom Kenyan adults are only weakly immunoreactive to PfRH5
16]. However, even single polymorphisms can lead to immune
vasion, as exempliﬁed by AMA1, where a few high-frequency
ariants can have a major effect on the speciﬁcity of the immune
esponse [31]. However, our study shows that at least in vitro, no
urrently identiﬁed common PfRH5 variant has a signiﬁcant effect
n the ability of anti-PfRH5 IgG to inhibit parasite growth. While
he SNPs tested here are based on the largest published whole P.
alciparum genome sequence analysis, additional high frequency
fRH5 SNPs may  be identiﬁed as more samples are sequenced.
owever, preliminary analysis of more than 1500 global clinical
solates does not reveal any additional PfRH5 SNPs present at higher
han 0.10 non-reference allele frequency in any geographic region
Malaria GEN unpublished data). The ﬁve SNPs investigated here
ay therefore represent the most common globally distributed
fRH5 polymorphisms that can be identiﬁed using current variation
alling pipelines.
Interestingly, previous sequencing of laboratory-adapted iso-
ates [13] identiﬁed eight additional PfRH5 SNPs (E48K, I204R,
204K, N347Y, N347D, Y358F, E362D, K429N) that have so far not
een seen in any clinical samples, all in strains with an increased
bility to invade Aotus erythrocytes [13]. It remains to be seen
hether these SNPs have arisen in laboratory strains spontaneously
uring in vitro culture, or whether they are present in natural iso-
ates at very low frequencies. However, what is clear is that P.
alciparum strains containing any of these eight SNPs would be non-
epresentative choices for vaccine challenges or antigen design. In
act the 3D7 PfRH5 sequence would also be a non-representative
hoice, because it contains the C203Y variant which is relatively
are in ﬁeld isolates.
In summary, using a mammalian expression system, we have
roduced full-length biochemically active recombinant PfRH5 that
an induce inhibitory antibodies to P. falciparum strains express-
ng all the currently identiﬁed common variants of PfRH5.  Broad
ross-inhibitory activities of anti-PfRH5 antibodies have previously
een demonstrated using virally delivered immunogen [16]. Our
tudy adds signiﬁcant new data to the vaccine candidacy of PfRH5,
y showing that the same strain-transcendent responses can be
nduced using a protein immunogen, and by extending the range of
ariants tested. There is therefore now a strong rationale to advance
his candidate to Phase I/IIa human trials, which, if successful, could
e combined with vaccines targeting other stages of the P. falcip-
rum life cycle, such as the sporozoite stage in the RTS, S, vaccine
urrently undergoing Phase III trials in Africa [25].
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